Adjuvant therapeutic efficacy of low-dose aspirin on short-term outcomes of patients with cancer-associated venous thromboembolism.

ABSTRACT:

Background

Although aspirin was reported to have primary thromboprophylactic efficacy on cancer patients, its adjuvant role in the treatment of patients with cancer-associated venous thromboembolism (VTE) has been unclear yet.

Methods

Patients with cancer-associated VTE were retrospectively analyzed and divided into aspirin group and non-aspirin group based on whether they underwent low-dose aspirin (100 mg daily) in addition to conventional anticoagulants. Propensity score matching was used to balance baseline characteristics between the aspirin group and non-aspirin group in a 1:2 ratio. The primary, secondary, and tertiary outcomes were VTE recurrence, mortality and major bleeding, and net clinical benefit (NCB), at 6 months after VTE diagnosis, respectively.

Results</

SUBMITTER: Xiong W 

PROVIDER: S-EPMC12306065 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature